DGAP-News: MorphoSys AG / Key word(s): Study results Planegg/Munich, Germany, May 19, 2017 MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the completion of the first part of a phase 1 clinical study in healthy volunteers with the investigational drug candidate MOR107 ahead of schedule. MOR107 is a selective agonist of the angiotensin II receptor type 2 (AT2-R), and is a lanthipeptide based on the proprietary technology platform of MorphoSys's subsidiary Lanthio Pharma. MOR107 is also the first lanthipeptide in MorphoSys's clinical pipeline. Based on an initial analysis of subjects enrolled to date, in all doses tested in this first-in-human trial, based on blinded data, there were no clinically relevant safety events seen, and all adverse events observed thus far were mild and transient in nature. Moreover a dose-dependent pharmacokinetic profile for MOR107 was observed. "We are very pleased with the initial data from the first part of the phase 1 clinical study of our MOR107 lanthipeptide in healthy volunteers conducted by our subsidiary Lanthio Pharma", commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "Preparations for the second part of the trial are ongoing." The study has been conducted by MorphoSys's fully owned subsidiary Lanthio Pharma B.V., Groningen, Netherlands. About Lanthio Pharma and MOR107 About MorphoSys HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=DIKRWJIXQN Document title: Media Release 19.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |